Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

about

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

Item

http://www.wikidata.org/entity/Q43689055

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@en

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@nl

type

Item

label

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@en

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@nl

prefLabel

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@en

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@nl

P1476

Pharmacokinetic interaction of ...... arallel-group clinical trials.

@en

P2093

Claudia Kasserra

http://www.w3.org/2001/XMLSchema#string

Edward O'Mara

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.

Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.

Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

P2888

11584560-000000000-00000

P304

267-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11584560-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009278280

http://www.w3.org/2001/XMLSchema#string

P698

21348539

http://www.w3.org/2001/XMLSchema#string